Goldman Sachs’s DiaMedica Therapeutics DMAC Stock Holding History

Goldman Sachs’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$401K	Sell	59,288 -70,100	-54%	-$555K	﹤0.01%	5738
2025 Q4	$1.03M	Buy	129,388 +52,096	+67%	+$390K	﹤0.01%	5117
2025 Q3	$531K	Buy	77,292 +59,388	+332%	+$322K	﹤0.01%	5475
2025 Q2	$69.8K	Sell	17,904 -103,898	-85%	-$405K	﹤0.01%	5878
2025 Q1	$462K	Buy	121,802 +52,854	+77%	+$302K	﹤0.01%	5235
2024 Q4	$374K	Buy	+68,948	New	+$325K	﹤0.01%	5396
2019 Q3	–	Sell	-51,061	Closed	-$253K	–	5208
2019 Q2	$253K	Buy	+51,061	New	+$177K	﹤0.01%	4686

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's DMAC Position: Q1 2026 in Review

Goldman Sachs reduced its DiaMedica Therapeutics (DMAC) stake by 54% in Q1 2026, selling an estimated $555K and leaving 59,288 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #5738.

Goldman Sachs first reported a position in DMAC in Q2 2019 and has held it in 7 quarters since. The position peaked at $1.03M in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Goldman Sachs held 59,288 shares of DiaMedica Therapeutics worth $401K as of Q1 2026.
Goldman Sachs sold 70,100 DiaMedica Therapeutics shares in Q1 2026, an estimated $555K.
DiaMedica Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5738 holding.
Goldman Sachs first reported a position in DiaMedica Therapeutics in Q2 2019 and has held it in 7 quarters since.
Goldman Sachs's DiaMedica Therapeutics position peaked at $1.03M in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.